{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:09Z","timestamp":1790312409912,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Thrombotic microangiopathies (TMA) require prompt identification and coordinated treatment because they are associated with substantial morbidity, irreversible target-organ injury, and mortality. Yet fragmented diagnostic and care pathways often delay diagnosis and lead to poorer outcomes. This Perspective article describes the design and implementation of a TMA Center of Excellence at a Brazilian quaternary hospital. This initiative aimed to design and implement a rapid-response, multidisciplinary TMA service to shorten diagnostic and treatment delays, standardize diagnosis-specific care, and establish prospective measures to evaluate clinical and operational performance. Rather than reporting outcomes, we highlight design choices, stewardship safeguards for high-cost therapies, and practical implementation enablers. Multidisciplinary teams designed and tested diagnostic and therapeutic workflows using iterative Plan\u2013Do\u2013Study\u2013Act cycles. Care pathways tailored to specific patient populations were embedded into the electronic medical record (EMR). EMR integration enabled real-time alerts triggered by key laboratory results, while embedded tools, such as the PLASMIC score (platelet count, hemolysis, no active cancer, no history of solid-organ or stem-cell transplant, mean corpuscular volume, international normalized ratio, and creatinine) and therapy-specific prescription menus, guided clinical decisions. A structured indicator framework was developed to prospectively monitor time to diagnosis, adherence to clinical pathways, length of stay, and intensive care utilization. Interdisciplinary collaboration facilitated alignment across emergency, radiology, laboratory, nephrology, and hematology services. This quality improvement strategy supports the feasibility of implementing a comprehensive, multidisciplinary model for TMA management and offers a transferable blueprint that middle-income health systems can adapt.<\/jats:p>","DOI":"10.3389\/fmed.2026.1944769","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:58Z","timestamp":1790310478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishing a rapid-response multidisciplinary service for thrombotic microangiopathies using a model of improvement framework: perspectives from a Brazilian quaternary hospital"],"prefix":"10.3389","volume":"13","author":[{"given":"Rosana Moreira Cosentino","family":"Penteado","sequence":"first","affiliation":[{"name":"Departamento de Patologia Cl\u00ednica, Medicina Diagn\u00f3stica, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Cristina","family":"D'Ornelas","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson Martins","family":"Ferreira Junior","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Souza Behr","family":"Pitoli","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Garcia","family":"de Barros","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Vernal","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ederson Haroldo Pereira","family":"de Almeida","sequence":"additional","affiliation":[{"name":"Escrit\u00f3rio de Excel\u00eancia em Sa\u00fade, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Carlos de Campos","family":"Guerra","sequence":"additional","affiliation":[{"name":"Departamento de Patologia Cl\u00ednica, Medicina Diagn\u00f3stica, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]},{"name":"Departamento de Oncologia e Hematologia, Hospital Israelita Albert Einstein","place":["S\u00e3o Paulo, SP, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","article-title":"How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"96","author":"George","year":"2000","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/ckj\/sfz040","article-title":"An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy","volume":"12","author":"Aigner","year":"2019","journal-title":"Clin Kidney J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e12708","DOI":"10.1002\/rth2.12708","article-title":"Thrombotic microangiopathies: an illustrated review","volume":"6","author":"Abou-Ismail","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.ajkd.2017.05.017","article-title":"Thrombotic microangiopathy: a multidisciplinary team approach","volume":"70","author":"Gordon","year":"2017","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.ackd.2021.11.006","article-title":"Thrombotic microangiopathy syndromes-common ground and distinct frontiers","volume":"29","author":"Hanna","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.mayocp.2016.05.015","article-title":"Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group","volume":"91","author":"Go","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ijlh.13954","article-title":"Diagnosis and treatment of thrombotic microangiopathy","volume":"44","author":"Thompson","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/imj.13804","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"48","author":"Fox","year":"2018","journal-title":"Intern Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20543581211008707","DOI":"10.1177\/20543581211008707","article-title":"Making the correct diagnosis in thrombotic microangiopathy: a narrative review","volume":"8","author":"McFarlane","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/art.42681","article-title":"Clinical evaluation and management of thrombotic microangiopathy","volume":"76","author":"Leisring","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B12","year":""},{"key":"B13","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH Guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH Guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 Focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British society for haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.tru.2024.100186","article-title":"Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies","volume":"16","author":"Evangelidis","year":"2024","journal-title":"Thromb Update"},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European society for blood and marrow transplantation, American society for transplantation and cellular therapy, Asia-Pacific blood and marrow transplantation group, and center for international blood and marrow transplant research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B19","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ijlh.13372","article-title":"Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLIA assay","volume":"43","author":"Montaruli","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jtct.2025.05.028","article-title":"An ASTCT, CIBMTR, EBMT, and APBMT consensus statement defining response criteria for hematopoietic cell transplantation associated thrombotic microangiopathy (TA-TMA) directed therapy","volume":"31","author":"Schoettler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e36188","DOI":"10.7759\/cureus.36188","article-title":"Role of the PLASMIC score in the management of thrombotic thrombocytopenic Purpura","volume":"15","author":"Vyas","year":"2023","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0206558","DOI":"10.1371\/journal.pone.0206558","article-title":"Impact of a multidisciplinary team for the management of thrombotic microangiopathy","volume":"13","author":"Uriol Rivera","year":"2018","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bjh.18902","article-title":"Clinical decision support to reduce unnecessary diagnostic testing for heparin-induced thrombocytopenia","volume":"202","author":"Gallo","year":"2023","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13012-020-01059-y","article-title":"Clinical decision support improves the appropriateness of laboratory test ordering in primary care without increasing diagnostic error: the ELMO cluster randomized trial","volume":"15","author":"Delvaux","year":"2020","journal-title":"Implement Sci iS"},{"key":"B26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jama.2021.25181","article-title":"The quintuple aim for health care improvement: a new imperative to advance health equity","volume":"327","author":"Nundy","year":"2022","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12882-024-03770-0","article-title":"Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts\u2019 perspectives with associated cost-consequence analysis","volume":"25","author":"Germeni","year":"2024","journal-title":"BMC Nephrol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0325417","DOI":"10.1371\/journal.pone.0325417","article-title":"The TMA team and TTP pathway improved outcomes in a cohort with thrombotic thrombocytopenic purpura","volume":"20","author":"Merrill","year":"2025","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American society for apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apheresis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA research collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1944769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:27:59Z","timestamp":1790310479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1944769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1944769"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1944769","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1944769"}}